Applicant, as named in the Orange Book
Msd
Next listed expiry: Januvia on 24 May 2027. 7 products with live protection, 0 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Januvia · 3 strengths sitagliptin phosphate | 24 May 2027 |
| Emend · 2 strengths aprepitant | 26 Sep 2027 |
| Prevymis · 2 strengths letermovir | 30 Aug 2031 |
| Idvynso doravirine; islatravir | 30 Aug 2032 |
| Verquvo · 3 strengths vericiguat | 26 Nov 2032 |
| Lipfendra enlicitide decanoate | 4 Feb 2040 |
| Ohtuvayre ensifentrine | 25 Jun 2044 |
Recent events
- 25 Oct 2026Januvia · Generic tentatively approved 17 Jul 2026
- 25 Oct 2026Januvia · Generic approved 20 Jan 2026
- 25 Oct 2026Januvia · Generic approved 14 Jan 2026
- 25 Oct 2026Januvia · Generic tentatively approved 26 Jan 2026
- 25 Oct 2026Januvia · First generic approved 29 Dec 2025
- 25 Oct 2026Januvia · Generic approved 29 Dec 2025
- 25 Oct 2026Januvia · Generic tentatively approved 24 Feb 2026
- 25 Oct 2026Verquvo · Generic tentatively approved 8 Apr 2026
- 25 Oct 2026Januvia · Generic tentatively approved 23 Feb 2026
- 25 Oct 2026Verquvo · Generic tentatively approved 20 Apr 2026
- 24 Oct 2026Januvia · Enters 12-month window basis: patent24 May 2027
- 24 Oct 2026Januvia · Enters 12-month window basis: patent24 May 2027
- 24 Oct 2026Januvia · Enters 12-month window basis: patent24 May 2027
- 24 Oct 2026Emend · Enters 12-month window basis: patent26 Sep 2027
- 24 Oct 2026Emend · Enters 12-month window basis: patent26 Sep 2027
- 24 Oct 2026Emend · Enters 12-month window basis: patent26 Sep 2027